Company: VRCA
Filing Date: 2025-05-13
Form Type: S-8
Source: 0001193125-25-118881
Chunk: 0

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-05-13
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on May 13, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Verrica Pharmaceuticals Inc. (Exact name of Registrant as specified in its charter)

| Delaware                        |     | 44 West Gay Street, Suite 400            
 West Chester, PA 19380                   |     | 46-3137900         |
| (State or other jurisdiction of 
 Incorporation or organization)  |     | -Address of principal executive offices) 
 (Zip code                                |     | -I.R.S. Employer   
 Identification No. |

2018 Equity Incentive Plan (Full title of the plan) Jayson Rieger President and Chief Executive Officer Verrica Pharmaceuticals Inc. 44 West Gay Street, Suite 400 West Chester, PA 19380 (Name and address of agent for service) (484) 453-3300 (Telephone number, including area code, of agent for service) Copies to: Darren DeStefano Mark Ballantyne Cooley LLP 11951 Freedom Drive Reston, VA 20190-5640 (703) 456-8000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☒ |     | Smaller reporting company |     | ☒ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

Pursuant to General Instruction E of Form S-8, Verrica Pharmaceuticals Inc. (the
“Registrant”) is filing this Registration Statement with the Securities and